



EUROPEAN COMMISSION

Directorate-General for Trade

Deputy Director General

Brussels, 24 September 2018

F.2[Art. 4.1(b)](2018) 5388484

NOTE FOR THE ATTENTION OF MARC VANHEUKELEN  
HEAD OF THE EU MISSION TO THE WTO

**Subject: Instructions for the regular meeting of the WTO Dispute Settlement  
Body on 26 September 2018**

**Summary:**

[Redacted]

[Out of Scope]

[Redacted]

Six returning and two new disputes are listed under **implementation surveillance**: the EU will provide its second status report on *Anti-Dumping Measures on Biodiesel from Indonesia* (DS480), and the status report on its implementation in *EC-Biotech* (DS 291) brought by the US.

[Redacted]

[Out of Scope]

[Redacted]

[Out of Scope]

[Redacted]

[Out of Scope]

[Redacted]

[Out of Scope]

[Redacted]

[Out of Scope]



[Redacted]  
[Out of Scope]  
[Redacted]

[Redacted]  
[Out of Scope]  
[Redacted]

[Redacted]  
[Out of Scope]  
[Redacted]  
[Redacted]  
[Redacted]  
[Redacted]  
[Redacted]

[Out of Scope]

[Redacted]  
[Out of Scope]

[Out of Scope]

[Redacted]  
[Out of Scope]  
[Redacted]

[Redacted]  
[Out of Scope]  
[Redacted]

C. EUROPEAN COMMUNITIES – MEASURES AFFECTING THE APPROVAL AND MARKETING OF BIOTECH PRODUCTS: STATUS REPORT BY THE EUROPEAN UNION (WT/DS291/37/ADD.125)

**Background**

In 2003, the US brought WTO proceedings regarding certain EU level and certain Member State level measures relating to the approval and marketing of biotech products claiming that these affected imports of agricultural and food imports from the United States.

Similar WTO proceedings were brought by Canada and Argentina (the three WTO proceedings were later merged into one single dispute, DS 291). The DSB adopted a panel report in November 2006, which found that the EU violated the SPS Agreement on three grounds:

- a) the EU applied a **general *de facto* moratorium** on approval of GM products between June 1999 and August 2003;
- b) **undue delays** in the completion of 21 product-specific approval procedures brought forward by the US (out of 25 cases considered by the Panel);

- c) **national safeguard measures** taken by 6 Member States, which were found not to be based on appropriate risk assessments.

On 19 December 2006, the EU informed the DSB of its intention to implement the Panel's recommendations and findings. The EU signed final settlements with CAN and with Argentina in 2010. The mutually agreed solutions provide for the establishment of regular bilateral dialogues on agricultural biotechnology market access issues of mutual interest.

Contrary to the other two complainants, the US did not consider the establishment of a dialogue sufficient in terms of compliance of the EU and thus, it was not ready to settle the dispute. To the contrary, it made a retaliation request on 17 January 2008, to which the EU objected. On 15 February 2008, and according to the sequencing agreement concluded with the US, both parties requested the suspension of the sanctions arbitration under Article 22.6 DSU. Those sanction arbitration procedures can only be resumed after conclusion of a compliance procedure based on Article 21.5 DSU.

An EU-US **technical dialogue on plant biotechnology** has been taking place on a regular basis since 2008. The last meeting took place on 17 July 2018.

**Recent EU developments**

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

- The ruling of the Court of Justice of the European Union concerning new mutagenesis techniques

The Court of Justice of the European Union was requested to give a preliminary ruling regarding the regulatory status of organisms produced by means of certain biotechnological techniques known as “new mutagenesis techniques”, and in particular on whether such techniques are exempted from the GMO-legislation. The Directive 2001/18/EC, on the deliberate release of GMOs, contains an exemption applicable to “mutagenesis techniques”, which already existed before the adoption of the Directive. The ruling was rendered on 25 July 2018.

The outcome of CJEU ruling is that the only organisms obtained by means of techniques or methods of mutagenesis, which have conventionally been used in a number of applications and have a long safety record, are exempted. **Therefore, the GMO legislation is applicable to organisms obtained by mutagenesis techniques, which have emerged since the adoption of Directive 2001/18/EC.**

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

### **Line to take**

The EU continues to be committed to acting in line with its WTO obligations.

### **Speaking points**

- [Out of Scope]
- [Out of Scope]

<sup>2</sup> Maize NK603 x MON 810.

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

- **[Defensive point on the Court ruling, if raised]**
- *In July, the Court of Justice of the European Union provided important clarification on the scope of application of the GMO legislation in relation to organisms obtained by mutagenesis techniques.*
- *The CJEU ruled that organisms obtained by means of new techniques/methods of mutagenesis, which have appeared or have been mostly developed since the adoption of Directive 2001/18, fall within the scope of the Directive.*
- *The Commission is now analysing the ruling to ensure its proper implementation.*

---

<sup>3</sup> Maize MON 87427 x MON 89034 x 1507 x MON 88017 x 59122.

- *Operators in and outside the EU remain responsible for ensuring that products which are placed on the market are safe and comply with all relevant regulatory requirements.*

[Redacted]  
[Redacted] [Out of Scope] [Redacted]  
[Redacted]

[Redacted] [Out of Scope] [Redacted]

[Redacted]  
[Redacted]  
[Redacted] [Out of Scope] [Redacted]  
[Redacted]  
[Redacted]  
[Redacted]  
[Redacted]  
[Redacted] [Out of Scope] [Redacted]  
[Redacted]  
[Redacted]  
[Redacted]  
[Redacted] [Out of Scope] [Redacted]  
[Redacted]  
[Redacted]  
[Redacted]  
[Redacted]  
[Redacted]  
[Redacted]  
[Redacted] [Out of Scope] [Redacted]  
[Redacted]  
[Redacted]

[Redacted] [Out of Scope] [Redacted]

[Redacted]  
[Redacted] [Out of Scope] [Redacted]  
[Redacted]  
[Redacted]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

[Out of Scope]

*[e-signed]*

Sandra GALLINA

C.c.: J-L. Demarty, H. König, S. Gallina, I. Garcia Bercero, P. Sandler, M. Martin-Prat, D. Redonnet, [Art. 4.1(b)] L. Rubinacci, [Art. 4.1(b)]

[Redacted text block]



[Art. 4.1(b)]  
[Art. 4.1(b)]  
[Art. 4.1(b)]  
[Art. 4.1(b)] – **DG TRADE**  
P. Velasco Martins - **Cabinet Malmström**  
[Art. 4.1(b)] – **EEAS**  
[Art. 4.1(b)] **DG GROW**  
J. Clarke, [Art. 4.1(b)] – **DG AGRI**  
[Art. 4.1(b)] – **DG ENER**  
[Art. 4.1(b)] M. Scannel [Art. 4.1(b)] ,  
[Art. 4.1(b)] – **DG SANTE**  
S. Henzler – **DG TAXUD**  
[Art. 4.1(b)] **SEC GEN**  
L. Romero Requena, [Art. 4.1(b)] ,  
– **WTO team Legal Service**  
[Art. 4.1(b)]  
– **Permanent Mission of the EU to the WTO**  
**EU DELEGATIONS:** Washington (US), Tokyo (Japan), Seoul (South Korea),  
Ottawa (Canada), Jakarta (Indonesia), Beijing (China), Canberra (Australia).